Related Experiment Video
Updated: Apr 21, 2026
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Construction of protein profile classification model and screening of proteomic signature of acute leukemia
Yun Xu1, Jiacai Zhuo2, Yonggang Duan1
1Central Laboratory, Shenzhen Second People's Hospital Shenzhen, Guangdong, China.
Insights
This study used proteomic signatures to classify acute leukemia subtypes, offering a new diagnostic approach. These protein profiles show potential for developing novel leukemia treatment and monitoring strategies.
Area of Science:
- Biochemistry
- Proteomics
- Hematology
Background:
- Current French-American-British (FAB) and WHO classifications for acute leukemia have limitations in differentiating subtypes and correlating with clinical outcomes.
- Accurate subtyping is crucial for effective treatment and prognosis in acute leukemia.
Purpose of the Study:
- To develop a proteomic-based classification model for acute leukemia subtypes.
- To identify novel proteomic signatures as potential biomarkers for leukemia diagnosis and monitoring.
Main Methods:
- Protein profiling of bone marrow mononuclear cells from acute leukemia patients and healthy volunteers using surface-enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF-MS).
- Construction of classification models based on 109 proteomic signatures to identify predictive markers.
- Screening and characterization of specific proteomic signatures (M3829, M1593, M2121, M2536, M1016) for different leukemia groups (CON, APL, AML-Gran, AML-Mon, ALL).
Main Results:
- Developed proteomic-based classification models capable of differentiating acute leukemia subtypes.
- Identified five key proteomic signatures (M3829, M1593, M2121, M2536, M1016) specific to different leukemia groups.
- Validated the classification model's credibility using Biomarker Patterns Software 5.0 (BPS 5.0) and clinical practice.
Conclusions:
- Proteomic signatures identified in leukemia blasts hold potential for new treatment and monitoring strategies.
- The developed proteomic-based classification model shows promise as a novel diagnostic approach for acute leukemia.
Abstract:
The French-American-British (FAB) and WHO classifications provide important guidelines for the diagnosis, treatment, and prognostic prediction of acute leukemia, but are incapable of accurately differentiating all subtypes, and not well correlated with the clinical outcomes. In this study, we performed the protein profiling of the bone marrow mononuclear cells from the patients with acute leukemia and the health volunteers (control) by surface enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI_TOF_MS). The patients with acute leukemia were analyzed as unitary by the profiling that were grouped into acute promyelocytic leukemia (APL), acute myeloid leukemia-granulocytic (AML-Gran), acute myeloid leukemia-monocytic (AML-Mon) acute lymphocytic leukemia (ALL), and control. Based on 109 proteomic signatures, the classification models of acute leukemia were constructed to screen the predictors by the improvement of the proteomic signatures and to detect their expression characteristics. According to the improvement and the expression characteristics of the predictors, the proteomic signatures (M3829, M1593, M2121, M2536, M1016) characterized successively each group (CON, APL, AML-Gra, AML-Mon, ALL) were screened as target molecules for identification. Meanwhile, the proteomic-based class of determinant samples could be made by the classification models. The credibility of the proteomic-based classification passed the evaluation of Biomarker Patterns Software 5.0 (BPS 5.0) scoring and validated application in clinical practice. The results suggested that the proteomic signatures characterized by different blasts were potential for developing new treatment and monitoring approaches of leukemia blasts. Moreover, the classification model was potential in serving as new diagnose approach of leukemia.
